ArticleSAGE open medical case reports2017
Therapeutic drug monitoring for colistin therapy in severe multi-resistant
Article in SAGE open medical case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Simultaneous Quantification of Colistin A and B in Human Plasma Using a Small Volume with a High-Throughput LC-MS/MS Method.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review.Antibiotics (Basel, Switzerland) · 2023Review
- Application of therapeutic drug monitoring to the treatment of bacterial central nervous system infection: a scoping review.The Journal of antimicrobial chemotherapy · 2022Article
- Quantification of Colistin in Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study.Scientific reports · 2020Article
- Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Spatio-Temporal Distribution ofMicroorganisms · 2020Review
- Critical care management of infectious meningitis and encephalitis.Intensive care medicine · 2020Article
- Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.The Journal of infection · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIntracranial infections due to multidrug- resistant (MDR) gram-negative pathogens are associated with increased morbidity and mortality. As therapeutic options are limited and systemic drug penetration into the infection focus is difficult, intraventricular therapy has been described.
methodsWe report on a patient with intracranial abscess caused by MDR Acinetobacter baumannii.
resultsHe was treated with high doses of intravenous and intraventricular colistin resulting in microbiological clearance and clinical cure. Therapy was controlled by therapeutic drug monitoring (TDM) of serum and liquor colistin levels. About 100 cases with intraventricular or intrathecal colistin are reported in literature but data on TDM are sparse.
conclusionsThis is one of the first cases providing data on TDM for locally administered high dose colistin therapy for the treatment of intracranial abscess formations. Based on these findings, increasing the intraventricular application interval paralleled with intravenous colistin could possibly be sufficient to achieve appropriate therapeutic drug levels. Further studies are needed to support alternative dosing strategies in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.